AP737A - New cryptophycins from synthesis. - Google Patents

New cryptophycins from synthesis. Download PDF

Info

Publication number
AP737A
AP737A APAP/P/1997/001069A AP9701069A AP737A AP 737 A AP737 A AP 737A AP 9701069 A AP9701069 A AP 9701069A AP 737 A AP737 A AP 737A
Authority
AP
ARIPO
Prior art keywords
taken together
group
methyl
compound
double bond
Prior art date
Application number
APAP/P/1997/001069A
Other languages
English (en)
Other versions
AP9701069A0 (en
Inventor
Richard E Moore
Marcus A Tius
Russell A Barrow
Jian Liang
Thomas H Corbett
Frederick A Valeriote
Thomas K Hemscheidt
Trimurtulu Golakoti
Original Assignee
Univ Hawaii
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/400,057 external-priority patent/US6013626A/en
Priority claimed from US08/482,141 external-priority patent/US5952298A/en
Application filed by Univ Hawaii, Univ Wayne State filed Critical Univ Hawaii
Publication of AP9701069A0 publication Critical patent/AP9701069A0/xx
Application granted granted Critical
Publication of AP737A publication Critical patent/AP737A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
APAP/P/1997/001069A 1995-03-07 1996-03-07 New cryptophycins from synthesis. AP737A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/400,057 US6013626A (en) 1993-12-21 1995-03-07 Cryptophycins from synthesis
US08/482,141 US5952298A (en) 1993-12-21 1995-06-07 Cryptophycins
PCT/US1996/003246 WO1996040184A1 (en) 1995-03-07 1996-03-07 New cryptophycins from synthesis

Publications (2)

Publication Number Publication Date
AP9701069A0 AP9701069A0 (en) 1997-10-30
AP737A true AP737A (en) 1999-03-15

Family

ID=27016884

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001069A AP737A (en) 1995-03-07 1996-03-07 New cryptophycins from synthesis.

Country Status (23)

Country Link
EP (1) EP0830136B1 (ro)
JP (1) JP4181632B2 (ro)
CN (1) CN1165337C (ro)
AP (1) AP737A (ro)
AT (1) ATE279935T1 (ro)
AU (1) AU723652B2 (ro)
BG (1) BG63289B1 (ro)
CZ (1) CZ278197A3 (ro)
DE (1) DE69633667T2 (ro)
ES (1) ES2230561T3 (ro)
FI (1) FI973591A0 (ro)
GE (1) GEP20002206B (ro)
HK (1) HK1009747A1 (ro)
HU (1) HU225041B1 (ro)
MD (1) MD2196B2 (ro)
NO (1) NO326685B1 (ro)
NZ (1) NZ305571A (ro)
OA (1) OA10614A (ro)
PL (1) PL185949B1 (ro)
RO (1) RO118931B1 (ro)
SK (1) SK119997A3 (ro)
TJ (1) TJ347B (ro)
WO (1) WO1996040184A1 (ro)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000501067A (ja) * 1995-08-30 2000-02-02 イーライ・リリー・アンド・カンパニー 医薬化合物
US6680311B1 (en) 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
JP2001500484A (ja) * 1996-08-30 2001-01-16 イーライ・リリー・アンド・カンパニー 医薬化合物の製造法
IL128610A (en) * 1996-08-30 2004-07-25 Lilly Co Eli Cryptophycin compound and its use as a medicament for treating neoplasm
EP0956295A1 (en) * 1996-09-06 1999-11-17 Eli Lilly And Company Process to prepare pharmaceutical compounds
KR20010029475A (ko) * 1996-09-06 2001-04-06 피터 지. 스트링거 약제학적 화합물의 제조 방법
JP2001502298A (ja) * 1996-09-06 2001-02-20 イーライ・リリー・アンド・カンパニー 方法および新規中間体
NZ336918A (en) * 1997-02-26 2001-11-30 Lilly Co Eli Selective epoxidation process for preparing pharmaceutical compounds comprising Cryptophycin 52
AU6338698A (en) * 1997-02-26 1998-09-18 Eli Lilly And Company Tripeptide and tetrapeptide pharmaceutical compounds
EP0870501A1 (en) * 1997-04-11 1998-10-14 Eli Lilly And Company Use of specific cryptophycin derivatives for the manufacture of a medicament in the treatment of fungal infections
EP0870506A1 (en) * 1997-04-11 1998-10-14 Eli Lilly And Company Compositions comprising a cryptophycin compound in combination with a synchronizing or activating agent for treating cancer
EP0870510A3 (en) * 1997-04-11 1999-09-15 Eli Lilly And Company Synergistic combination comprising cryptophycin derivatives and microtubule synergizing agents
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
US6376230B1 (en) 1998-10-16 2002-04-23 Eli Lilly And Company Stereoselective process for producing intermediates of cryptophycins
AU1123200A (en) * 1998-10-16 2000-05-08 Eli Lilly And Company Stereoselective process for producing antineoplastic agents
WO2000034252A2 (en) * 1998-12-07 2000-06-15 Eli Lilly And Company Process for the preparation of cryptophycin derivatives
US6372936B1 (en) * 1999-06-09 2002-04-16 Eli Lilly And Company Optical resolution of aminoisobobutyric acid
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
US11530204B2 (en) * 2019-09-30 2022-12-20 The Regents Of The University Of Michigan Biocatalytic synthesis of cryptophycin anticancer agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946835A (en) * 1988-07-15 1990-08-07 Merck & Co., Inc. Antifungal fermentation product and method
US4868208A (en) * 1988-07-15 1989-09-19 Merck & Co., Inc. Antifungal agent and method
US4845086A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
US4845085A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
WO1995017093A1 (en) * 1993-12-21 1995-06-29 University Of Hawaii New cryptophycins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL PHARMACEUTICAL BULLETIN, 42(10), ISSUED 1994, KOBAYASHI et al., "The Absolute Stereostructure of Arenastatin A, A Potent Cytotoxic Depsipeptide from the Okinawan Marine Sponge Dysidea Arenaria", pages 2196-2198 *
FEBS Letters, issued 1995 KERKSIEK et al., "Interaction fo Cryptophycin 1 with Tubulin and Microtubules", pages 59-61 *

Also Published As

Publication number Publication date
ES2230561T3 (es) 2005-05-01
NO974105L (no) 1997-11-05
HK1009747A1 (en) 1999-06-11
EP0830136B1 (en) 2004-10-20
JP4181632B2 (ja) 2008-11-19
CN1165337C (zh) 2004-09-08
TJ347B (en) 2002-10-06
PL322507A1 (en) 1998-02-02
NO326685B1 (no) 2009-01-26
MD2196B2 (ro) 2003-06-30
JPH11510476A (ja) 1999-09-14
BG101875A (en) 1998-10-30
OA10614A (en) 2001-03-15
ATE279935T1 (de) 2004-11-15
WO1996040184A1 (en) 1996-12-19
CN1183726A (zh) 1998-06-03
HUP9801880A2 (hu) 1998-11-30
BG63289B1 (bg) 2001-09-28
MD970313A (ro) 1999-06-30
FI973591A0 (fi) 1997-09-03
AU5360396A (en) 1996-12-30
EP0830136A1 (en) 1998-03-25
GEP20002206B (en) 2000-08-25
DE69633667D1 (en) 2004-11-25
HU225041B1 (en) 2006-05-29
RO118931B1 (ro) 2004-01-30
CZ278197A3 (cs) 1998-12-16
DE69633667T2 (de) 2006-03-02
HUP9801880A3 (en) 1999-08-30
PL185949B1 (pl) 2003-09-30
EP0830136A4 (en) 2001-01-24
AP9701069A0 (en) 1997-10-30
NZ305571A (en) 1999-02-25
AU723652B2 (en) 2000-08-31
NO974105D0 (no) 1997-09-05
SK119997A3 (en) 1998-12-02

Similar Documents

Publication Publication Date Title
AP737A (en) New cryptophycins from synthesis.
CA2149150C (en) Injectable taxol composition with improved stability
Speicher et al. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines
US5206018A (en) Use of rapamycin in treatment of tumors
US5541232A (en) Treatment of multidrug resistant diseases
US6013626A (en) Cryptophycins from synthesis
CA1302270C (en) Carcinostatic agent
EA006483B1 (ru) Замещенные триазолопиримидины в качестве противораковых средств
Guzmán et al. Leiodermatolide, a novel marine natural product, has potent cytotoxic and antimitotic activity against cancer cells, appears to affect microtubule dynamics, and exhibits antitumor activity
NZ258044A (en) Pharmaceutical composition comprising taxol, solubilising agent, an acid and an organic solvent
US20080125479A1 (en) Wortmannin analogs and methods of using same
KR100459527B1 (ko) 합성된신규한크립토파이신
Hsieh et al. Kalanchoe tubiflora extract inhibits cell proliferation by affecting the mitotic apparatus
CA2458318C (en) Wortmannin analogs and methods of using same
CN110563743A (zh) 一种肿瘤靶向青蒿素衍生物
WO1996039829A9 (en) New cryptophycins
KR890017252A (ko) 티에노트리아졸로디아제핀 화합물 및 그의 약학적 용도
KR19990082064A (ko) 피페라진 옥시란 유도체를 사용하여 신생 세포의 사멸을유도하는 방법
EP1850851A2 (en) Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines
AU597478B2 (en) 3-(2-haloethyl)-1,4-oxathiins and 2-(2-haloethyl)-1,4-dithiins and treatment of leukemia and tumors therewith
US5955423A (en) Cryptophycins
US20030105357A1 (en) Helianthrone derivatives as anti-cancer agents
RU2195458C2 (ru) Криптофициновое соединение, фармацевтическая композиция, способ ингибирования пролиферации клеток и способ смягчения патологического состояния
CA2214565C (en) New cryptophycins from synthesis
AU2008201477A1 (en) Wortmannin analogs and methods of using same